FPT-SOFTWARE/SCSK-EU
19.4.2022 05:02:12 CEST | Business Wire | Press release
Vietnam’s leading Digital Transformation services provider FPT Software has recently unveiled its partnership with SCSK Europe, a subsidiary of the Japan-based system integrator SCSK Corporation. The collaboration affirms FPT Software’s robotic process automation (RPA) expertise and further expands its foothold in the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005262/en/
Applying “Fast Automation” framework, FPT Software has successfully helped SCSK Europe streamline six internal processes by deploying its award-winning RPA platform akaBot in four weeks. The offshore team then provided a comprehensive understanding of RPA’s benefits and armed SCSK employees with the necessary skills and mentality for the upcoming changes with the emergence of digital transformation. Following their internal success, SCSK Europe introduced FPT Software’s akaBot to their clients in the Chemical and Agriculture industries to help replace 100 percent human effort in their data extraction and loan credits approval processes.
"RPA is a powerful tool to resolve the bottleneck in business processes, delivering a much streamlined and efficient workflow. We believe that we can always extend the automation horizons even more by integrating RPA robots with other intelligent technologies,” said Masatoshi Chiba – General Manager, SCSK EU.
“With that expectation in mind, we decided to partner with akaBot, one of the leading vendors in developing hyper-automation solutions from FPT. Since 2018, we have established MOU for the comprehensive partnership to seek to supply a wider range of services and solutions and to expand our operations in the global through this partnership with FPT," Masatoshi Chiba further shared.
According to FPT Software Chief Operating Officer Tran Dang Hoa, the collaboration "paved the way for FPT Software’s expansion in robotic automation and digital transformation in the EU and on a global scale."
"Like SCSK, more and more firms worldwide are adopting RPA and hyper-automation to enhance operations," Tran Dang Hoa said. "As a global top 30 RPA solution provider, we aspire to accompany businesses to overcome pressing challenges, boost their productivity and save costs," he added.
FPT Software and SCSK’s partnership dates back to 2018 when the two cooperated in supporting the overseas expansion of Japanese companies, especially in financial and automotive systems development. Both sides joined forces in providing IT Services and business development through the Asia Pacific operations of major SCSK’s shareholder – Sumitomo Corporation.
First entering the European market in 2008, FPT Software has established seven offices and development centers, and is determined to penetrate further with digital transformation as the key driving force. The global IT firm targeted this strategic area as its first port for capital commitment in the value of 100 million dollars in the upcoming years, with the UK and Germany as two major geographies.
About FPT Software
FPT Software is a global technology and IT services provider headquartered in Vietnam, with USD 632.5 million in revenue and 22,500 employees in 26 countries. As a pioneer in digital transformation, the company delivers world-class services in Smart factories, Digital platforms, RPA, AI, IoT, Cloud, AR/VR, BPO, and more. It has served 700+ customers worldwide, a hundred of which are Fortune Global 500 companies in the industries of Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For further information, please visit http://www.fpt-software.com .
About SCSK EU
SCSK Europe Ltd. was established in London in 1990 as a fully-owned subsidiary of SCSK Corporation, one of Japan's leading IT service companies with more than 14,000 employees. We are One Stop IT Service Provider and a proven strategic business partner to Japanese-related corporations operating in EMEA/CIS providing various IT Solutions including RPA. For further information, please visit SCSK Europe Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005262/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom